One week after implantation, we confirmed tumor formation (volumes of 100–200 mm3) by ultrasound, after which mice were divided into treatment arms with similar tumor volume distributions (n = 8–10/group): (a) KPC implants, BLU9931 treatment (twice daily oral gavage); b) KPC implants, vehicle control (twice daily oral gavage); c) KPC-Hmga1 heterozygous implants, BLU9931 treatment; and (d) KPC-Hmga1 heterozygous implants, vehicle control. The gene discussed is HMGA1; the disease is neoplasm.